Merck’s 2025 guidance fell short of Wall Street expectations. - Spencer Platt/Getty Images Investors have taken to punishing pharma companies that appear unable to gauge demand for their top ...

Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Also Read: RJK Jr.'s Involvement In Merck Lawsuit Faces Scrutiny Ahead Of Senate Hearing The pharmaceutical unit booked $14.04 billion in revenue, up 7% year over year (+8% ex-exchange).

That R&D takes place not only at big pharma companies—household names such as Pfizer and Merck—but also at smaller, less well-known but no less heroic biosciences startups, such as Vivek ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.

Merck MRK-0.87%decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Merck shares tumbled after the drugmaker said ... In results published on Tuesday, the pharmaceutical group forecast full-year sales of between $64.1bn and $65.6bn in 2025, broadly flat compared ...

Merck (MRK) stock was mangled today after the pharmaceutical and vaccine company released its guidance for 2025. The company expects adjusted earnings per share for the year to range from $8.88 to ...